Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FUTURE SCI LTD
Autores
Citação
BIOANALYSIS, v.14, n.15, p.1039-1050, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Tweetable abstract Thalidomide measurement in dried plasma spot by ultra-HPLC-MS/MS combined with online SPE was successfully validated and applied in therapeutic drug monitoring. #thalidomide #DPS #chromatography #mass spectrometry Aims: To validate an SPE-ultra-HPLC-MS/MS method for thalidomide (THD) measurement in dried plasma spot (DPS). Methods: Extraction included acetonitrile/water clean-up and online SPE. The LOD, LLOQ, linearity, precision, accuracy, recovery, matrix effect, process efficiency, carryover, stability, drug interference and dilution integrity were assessed. Results: The method was linear from 50 to 2000 ng/ml with a LOD of 20 ng/ml and LLOQ of 50 ng/ml. The coefficient of variation for precision was 0.4-7.9% for intra-assay and 1.3-8.9% for interassay and accuracy was 81.4-97.1%. Adequate matrix effect (100.6-107.0%), recovery (88.7-105.0%) and process efficiency (91.3-109.3%) were registered. DPS was stable for 14 days at room temperature and 45 degrees C and for 4 months at -80 degrees C. The method was applied to quantify THD in both wet plasma and DPS from patients with cutaneous lupus receiving THD treatment. The difference between THD wet plasma and DPS concentration was Conclusion: The method is suitable to quantify THD in DPS.
Palavras-chave
dried plasma spot, liquid chromatography, mass spectrometry, method validation, thalidomide
URI
https://observatorio.fm.usp.br/handle/OPI/49309
Referências
  1. Bai N, 2013, EXP THER MED, V5, P626, DOI 10.3892/etm.2012.847
  2. Bartlett JB, 2004, NAT REV CANCER, V4, P314, DOI 10.1038/nrc1323
  3. Jacques ALB, 2022, FORENSIC SCI MED PAT, V18, P86, DOI 10.1007/s12024-021-00434-5
  4. Capiau S, 2019, THER DRUG MONIT, V41, P409, DOI 10.1097/FTD.0000000000000643
  5. Chasset F, 2018, J AM ACAD DERMATOL, V78, P342, DOI 10.1016/j.jaad.2017.09.059
  6. Clinical and Laboratory Standards Institute (CLSI), 2007, C50A CLSI
  7. Clinical and Laboratory Standards Institute (CLSI), 2006, EP15A2 CLSI
  8. Clinical and Laboratory Standards Institute (CLSI), 2003, EP6A CLSI
  9. Cuadrado MJ, 2005, AM J MED, V118, P246, DOI 10.1016/j.amjmed.2004.04.030
  10. De Rose DU, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165898
  11. Dinur T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031627
  12. Eliasson E, 2013, EUR J CLIN PHARMACOL, V69, pS25, DOI 10.1007/s00228-013-1504-x
  13. Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis-2019-215089
  14. *FDA, 2018, BIOAN METH VAL GUID
  15. Filali-Ansary A, 2016, THER DRUG MONIT, V38, P471, DOI 10.1097/FTD.0000000000000302
  16. Frankel Hillary C, 2013, Int J Dermatol, V52, P1407, DOI 10.1111/j.1365-4632.2011.05200.x
  17. Gaspar VP, 2021, J MASS SPECTROM, V56, DOI 10.1002/jms.4788
  18. Gordon JN, 2003, POSTGRAD MED J, V79, P127, DOI 10.1136/pmj.79.929.127
  19. Howie SRC, 2011, B WORLD HEALTH ORGAN, V89, P46, DOI 10.2471/BLT.10.080010
  20. Iacuzzi V, 2021, PHARM RES-DORDR, V38, P759, DOI 10.1007/s11095-021-03036-6
  21. International Council for Harmonisation (ICH) Guideline, 2022, BIOAN METH VAL STUD
  22. Jiang F., 2018, BIOMED CHROMATOGR, V32, P1
  23. Kakimoto T, 2002, JPN J CANCER RES, V93, P1029, DOI 10.1111/j.1349-7006.2002.tb02480.x
  24. Kodama T, 2009, CLIN LYMPHOMA MYELOM, V9, P154, DOI 10.3816/CLM.2009.n.037
  25. Kole PL, 2011, BIOMED CHROMATOGR, V25, P199, DOI 10.1002/bmc.1560
  26. Li WK, 2010, BIOMED CHROMATOGR, V24, P49, DOI 10.1002/bmc.1367
  27. Lopez-Ruiz R, 2019, TRAC-TREND ANAL CHEM, V118, P170, DOI 10.1016/j.trac.2019.05.044
  28. Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s
  29. Yuki EFN, 2021, JCR-J CLIN RHEUMATOL, V27, P248, DOI 10.1097/RHU.0000000000001160
  30. Qu Y, 2017, J PHARMACEUT BIOMED, V140, P334, DOI 10.1016/j.jpba.2017.03.047
  31. Ribatti D, 2005, LEUKEMIA, V19, P1525, DOI 10.1038/sj.leu.2403852
  32. Roche S, 2012, J CHROMATOGR B, V902, P16, DOI 10.1016/j.jchromb.2012.06.008
  33. SAMSOEN M, 1980, ANN DERMATOL VENER, V107, P515
  34. Shu C, 2016, J CHROMATOGR B, V1028, P111, DOI 10.1016/j.jchromb.2016.06.009
  35. Silveira LP, 2022, J ONCOL PHARM PRACT, V28, P373, DOI 10.1177/1078155221993528
  36. Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102
  37. Stevens RJ, 1997, BRIT J RHEUMATOL, V36, P353
  38. Teo SK, 2002, J CHROMATOGR B, V767, P145, DOI 10.1016/S1570-0232(01)00563-3
  39. Trifonova OP, 2019, METABOLITES, V9, DOI 10.3390/metabo9110277
  40. Verougstraete N, 2022, J PHARMACEUT BIOMED, V207, DOI 10.1016/j.jpba.2021.114418
  41. Wilhelm AJ, 2014, CLIN PHARMACOKINET, V53, P961, DOI 10.1007/s40262-014-0177-7
  42. Yuki EFN, 2021, LUPUS, V30, P956, DOI 10.1177/0961203321998433

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/17
Carregar mais